Literature DB >> 30642904

Moderately Neutralizing Epitopes in Nonfunctional Regions Dominate the Antibody Response to Plasmodium falciparum EBA-140.

Nichole D Salinas1, May M Paing2, Jagat Adhikari3, Michael L Gross3, Niraj Tolia4.   

Abstract

Plasmodium falciparum erythrocyte-binding antigen 140 (EBA-140) plays a role in tight junction formation during parasite invasion of red blood cells and is a potential vaccine candidate for malaria. Individuals in areas where malaria is endemic possess EBA-140-specific antibodies, and individuals with high antibody titers to this protein have a lower rate of reinfection by parasites. The red blood cell binding segment of EBA-140 is comprised of two Duffy-binding-like domains, called F1 and F2, that together create region II. The sialic acid-binding pocket of F1 is essential for binding, whereas the sialic acid-binding pocket in F2 appears dispensable. Here, we show that immunization of mice with the complete region II results in poorly neutralizing antibodies. In contrast, immunization of mice with the functionally relevant F1 domain of region II results in antibodies that confer a 2-fold increase in parasite neutralization compared to that of the F2 domain. Epitope mapping of diverse F1 and F2 monoclonal antibodies revealed that the functionally relevant F1 sialic acid-binding pocket is a privileged site inaccessible to antibodies, that the F2 sialic acid-binding pocket contains a nonneutralizing epitope, and that two additional epitopes reside in F1 on the opposite face from the sialic acid-binding pocket. These studies indicate that focusing the immune response to the functionally important F1 sialic acid binding pocket improves the protective immune response of EBA-140. These results have implications for improving future vaccine designs and emphasize the importance of structural vaccinology for malaria.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Plasmodium falciparumzzm321990; antibody function; epitope; immunogen design; malaria; structural vaccinology; three-dimensional structure; vaccines

Mesh:

Substances:

Year:  2019        PMID: 30642904      PMCID: PMC6434137          DOI: 10.1128/IAI.00716-18

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  61 in total

1.  Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum.

Authors:  B K Sim; C E Chitnis; K Wasniowska; T J Hadley; L H Miller
Journal:  Science       Date:  1994-06-24       Impact factor: 47.728

2.  Structural basis for the EBA-175 erythrocyte invasion pathway of the malaria parasite Plasmodium falciparum.

Authors:  Niraj H Tolia; Eric J Enemark; B Kim Lee Sim; Leemor Joshua-Tor
Journal:  Cell       Date:  2005-07-29       Impact factor: 41.582

3.  Reticulocyte and erythrocyte binding-like proteins function cooperatively in invasion of human erythrocytes by malaria parasites.

Authors:  Sash Lopaticki; Alexander G Maier; Jennifer Thompson; Danny W Wilson; Wai-Hong Tham; Tony Triglia; Alex Gout; Terence P Speed; James G Beeson; Julie Healer; Alan F Cowman
Journal:  Infect Immun       Date:  2010-12-13       Impact factor: 3.441

4.  Crystal and solution structures of Plasmodium falciparum erythrocyte-binding antigen 140 reveal determinants of receptor specificity during erythrocyte invasion.

Authors:  Daniel H Lin; Brian M Malpede; Joseph D Batchelor; Niraj H Tolia
Journal:  J Biol Chem       Date:  2012-09-18       Impact factor: 5.157

5.  Molecular basis for sialic acid-dependent receptor recognition by the Plasmodium falciparum invasion protein erythrocyte-binding antigen-140/BAEBL.

Authors:  Brian M Malpede; Daniel H Lin; Niraj H Tolia
Journal:  J Biol Chem       Date:  2013-03-18       Impact factor: 5.157

Review 6.  The Molecular Basis of Erythrocyte Invasion by Malaria Parasites.

Authors:  Alan F Cowman; Christopher J Tonkin; Wai-Hong Tham; Manoj T Duraisingh
Journal:  Cell Host Microbe       Date:  2017-08-09       Impact factor: 21.023

7.  Structural analysis of the synthetic Duffy Binding Protein (DBP) antigen DEKnull relevant for Plasmodium vivax malaria vaccine design.

Authors:  Edwin Chen; Nichole D Salinas; Francis B Ntumngia; John H Adams; Niraj H Tolia
Journal:  PLoS Negl Trop Dis       Date:  2015-03-20

8.  Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies.

Authors:  Katherine E Wright; Kathryn A Hjerrild; Jonathan Bartlett; Alexander D Douglas; Jing Jin; Rebecca E Brown; Joseph J Illingworth; Rebecca Ashfield; Stine B Clemmensen; Willem A de Jongh; Simon J Draper; Matthew K Higgins
Journal:  Nature       Date:  2014-08-17       Impact factor: 49.962

9.  The epitope of monoclonal antibodies blocking erythrocyte invasion by Plasmodium falciparum map to the dimerization and receptor glycan binding sites of EBA-175.

Authors:  Xavier Ambroggio; Lubin Jiang; Joan Aebig; Harold Obiakor; Jan Lukszo; David L Narum
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

10.  Critical glycosylated residues in exon three of erythrocyte glycophorin A engage Plasmodium falciparum EBA-175 and define receptor specificity.

Authors:  Nichole D Salinas; May M Paing; Niraj H Tolia
Journal:  mBio       Date:  2014-09-09       Impact factor: 7.867

View more
  3 in total

Review 1.  Getting in: The structural biology of malaria invasion.

Authors:  Hirdesh Kumar; Niraj H Tolia
Journal:  PLoS Pathog       Date:  2019-09-05       Impact factor: 6.823

2.  Nanoscale binding site localization by molecular distance estimation on native cell surfaces using topological image averaging.

Authors:  Vibha Kumra Ahnlide; Johannes Kumra Ahnlide; Sebastian Wrighton; Jason P Beech; Pontus Nordenfelt
Journal:  Elife       Date:  2022-02-24       Impact factor: 8.140

3.  Neutralizing and interfering human antibodies define the structural and mechanistic basis for antigenic diversion.

Authors:  Palak N Patel; Thayne H Dickey; Christine S Hopp; Ababacar Diouf; Wai Kwan Tang; Carole A Long; Kazutoyo Miura; Peter D Crompton; Niraj H Tolia
Journal:  Nat Commun       Date:  2022-10-06       Impact factor: 17.694

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.